# Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

> **NCT03445949** · PHASE4 · RECRUITING · sponsor: **National Institute of Cardiology, Warsaw, Poland** · enrollment: 200 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** short postimplantation dual antiplatelet therapy
- **DRUG:** extended postimplantation dual antiplatelet therapy
- **DRUG:** long-term treatment with a single antiplatelet agent
- **DRUG:** 6 months treatment with a single antiplatelet agent

## Key facts

- **NCT ID:** NCT03445949
- **Lead sponsor:** National Institute of Cardiology, Warsaw, Poland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-23
- **Primary completion:** 2025-06-23
- **Final completion:** 2027-06-23
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445949, "Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03445949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*